Time:June 10-11, 2015
Country&Region: United States
Venue:Westin Boston Waterfront,Boston,MA
Organizer:Cambridge Healthtech Institute
New screening technologies, in vitro assays and in vivo models continue to be developed, but is the right tool being used at the right time to predict and detect adverse events? Cambridge Healthtech Institute’s eighth annual conference on New Models for Predicting Drug Toxicity, looks at the scientific and technological progress being made to better predict drug-related toxicities at the preclinical stage, and avoid costly mistakes in the clinic.
Preliminary Agenda | Speaker Biographies
EFFECTIVE USE OF IN VITRO AND IN VIVO MODELS
KEYNOTE PRESENTATION: Mice with ‘Humanized’ Livers: From Safer Drugs to Liver Regeneration
Gary Peltz, M.D., Ph.D., Professor, Anesthesia, Stanford University
Assay Platforms for Toxicity Evaluation in Small Molecules and Nanomaterials
Robert Damoiseaux, Ph.D., Scientific Director, Molecular Screening Shared Resource California Nanosystems Institute, University of California, Los Angeles
Current Use of Stem Cell-Derived Cardiomyocytes to Assess QT Prolongation and Proarrhythmia
Bernard Fermini, Ph.D., Associate Research Fellow, Global Safety Pharmacology, Pfizer Global Research & Development
How Useful Are in vitro Tools to Predict Hyperbilirubinemia: Utility of UGT1A1, OATP1B1, OATP1B3, MRP2 and BSEP Inhibition Assays
Jae Chang, Ph.D., Senior Scientist, DMPK, Genentech
Proteomic Approaches to the Discovery of Preclinical Biomarkers of Toxicity
Li-Rong Yu, Ph.D., Associate Co-Director, Biomarkers and Alternative Models Branch Division of Systems Biology, National Center for Toxicological Research, U.S. Food and Drug Administration
EXPLORING ENGINEERED MODELS
Body-on-a-Chip Devices for Drug Testing: Opportunities and Limitations
Michael Shuler, Ph.D., Samuel B. Eckert Professor of Chemical Engineering and James and Marsha McCormick Chair of Biomedical Engineering, Cornell University
Tissue Chips for Drug Discovery and Screening
Kristin Fabre, Ph.D., Scientific Program Manager, Tissue Chip for Drug Screening Program, National Center for Advancing Translational Sciences (NCATS), NIH
Human Contractile Engineered Muscle for Drug and Toxicity Studies
Nenad Bursac, Ph.D., Rooney Family Associate Professor, Department of Biomedical Engineering, Duke University
Towards Organoid Microarrays for Pan-Hindbrain and Spinal Cord Screening
Krishanu Saha, Ph.D., Assistant Professor, Department of Biomedical Engineering and Bioethics, University of Wisconsin-Madison
PREDICTIVITY OF COMPUTATIONAL TOOLS
Enhanced Prediction of Drug-Induced Liver Injury by the Development of Liver Toxicity Knowledge Base
Minjun Chen, Ph.D., Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration
An in silico Approach to Predict Intrinsic in vitro Cytotoxicity for Compounds in Primary Human Hepatocytes
BinQing Wei, Ph.D., Scientist, Discovery Chemistry, Genentech
Bioinformatic and Cheminformatic Approaches to Assess Cardiac Arrhythmias
Siobhan Malany, Ph.D., Chemical Biology Team Leader, Chemical Genomics Center, Sanford Burnham Medical Research Institute
For questions or suggestions about the meeting, please contact:
Tanuja Koppal, Ph.D.
Conference Director
Cambridge Healthtech Institute
T: (+1) 973-525-4667
E: tkoppal@healthtech.com
For sponsorship and exhibit sales information including sponsored podium presentations, contact:
Joseph Vacca
Associate Director, Business Development
Cambridge Healthtech Institute
T: (+1) 781-972-5431
E: jvacca@healthtech.com
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: